MX2010004482A - Anticuerpos anti-proteina g vsr. - Google Patents

Anticuerpos anti-proteina g vsr.

Info

Publication number
MX2010004482A
MX2010004482A MX2010004482A MX2010004482A MX2010004482A MX 2010004482 A MX2010004482 A MX 2010004482A MX 2010004482 A MX2010004482 A MX 2010004482A MX 2010004482 A MX2010004482 A MX 2010004482A MX 2010004482 A MX2010004482 A MX 2010004482A
Authority
MX
Mexico
Prior art keywords
rsv
protein antibodies
protein
fragments
bind
Prior art date
Application number
MX2010004482A
Other languages
English (en)
Spanish (es)
Inventor
Orit Foord
Lawrence M Kauvar
Ellen J Collarini
Bruce Keyt
Original Assignee
Trellis Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trellis Bioscience Inc filed Critical Trellis Bioscience Inc
Publication of MX2010004482A publication Critical patent/MX2010004482A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
MX2010004482A 2007-10-25 2008-10-24 Anticuerpos anti-proteina g vsr. MX2010004482A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46907P 2007-10-25 2007-10-25
US8940108P 2008-08-15 2008-08-15
PCT/US2008/081175 WO2009055711A2 (en) 2007-10-25 2008-10-24 Anti-rsv g protein antibodies

Publications (1)

Publication Number Publication Date
MX2010004482A true MX2010004482A (es) 2010-07-06

Family

ID=40580419

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004482A MX2010004482A (es) 2007-10-25 2008-10-24 Anticuerpos anti-proteina g vsr.

Country Status (14)

Country Link
US (3) US7736648B2 (enExample)
EP (1) EP2214711B1 (enExample)
JP (2) JP5808536B2 (enExample)
KR (1) KR101671452B1 (enExample)
CN (1) CN101808663B (enExample)
AU (1) AU2008316703B2 (enExample)
BR (1) BRPI0819210A2 (enExample)
CA (1) CA2703667C (enExample)
IL (1) IL205257A (enExample)
MX (1) MX2010004482A (enExample)
NZ (1) NZ585589A (enExample)
RU (1) RU2526517C2 (enExample)
WO (1) WO2009055711A2 (enExample)
ZA (1) ZA201003131B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040156888A1 (en) * 2002-11-26 2004-08-12 Jensen Gerard M. Liposomal formulations
NZ585589A (en) * 2007-10-25 2012-07-27 Trellis Bioscience Inc Anti-rsv g protein antibodies
WO2013095091A2 (en) 2011-11-17 2013-06-27 Aimm Therapeutics B.V. Rsv g protein specific antibodies
US10131709B2 (en) 2011-12-28 2018-11-20 Immunoqure Ag Nucleic acid molecules encoding monoclonal antibodies specific for IL-22
AU2013206788B2 (en) * 2011-12-28 2017-11-30 Immunoqure Ag Method of providing monoclonal auto-antibodies with desired specificity
US9546219B2 (en) 2012-02-08 2017-01-17 North Carolina State University Treatment of allergic diseases with recombinant antibodies
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
US10035842B2 (en) 2013-04-15 2018-07-31 Janssen Vaccines & Prevention B.V. Human antibodies binding to RSV G proteins
CN111303278B (zh) * 2013-04-15 2022-09-06 扬森疫苗与预防公司 结合到rsv g蛋白的人类抗体
WO2014170257A1 (en) * 2013-04-15 2014-10-23 Crucell Holland B.V. Human antibodies binding to rsv g protein
WO2015120474A1 (en) * 2014-02-10 2015-08-13 Igm Biosciences, Inc. Iga multi-specific binding molecules
CN103911389A (zh) * 2014-04-09 2014-07-09 南昌大学 一种检测人呼吸道合胞病毒抗体的g和f蛋白的制备方法
RS62870B1 (sr) 2014-12-05 2022-02-28 Memorial Sloan Kettering Cancer Center Himerni antigenski receptori sa ciljanim delovanjem na receptore spregnute sa g-proteinom i njihove upotrebe
SG10201913937QA (en) 2014-12-05 2020-03-30 Memorial Sloan Kettering Cancer Center Antibodies targeting g-protein coupled receptor and methods of use
CN106496324B (zh) * 2015-11-30 2020-01-14 天津昊免生物技术有限公司 一种抗呼吸道合胞病毒的全人源抗体
CN105542003B (zh) * 2016-03-01 2019-12-06 苏州博泰神州生物技术有限公司 一种针对rsv粘附g蛋白表面抗原的全人源单克隆抗体
EP3538558A4 (en) 2016-11-09 2020-07-15 North Carolina State University TREATMENT OF ALLERGIC DISEASES USING CHIMERIC PROTEIN
SG11201906682YA (en) 2017-01-27 2019-08-27 Ngm Biopharmaceuticals Inc Glucagon receptor binding proteins and methods of use thereof
WO2019075400A1 (en) * 2017-10-13 2019-04-18 Trellis Bioscience, Llc CONFORMATIONAL EPITOPES IN A CENTRAL PROTECTED REGION OF SYNCYTIAL RESPIRATORY VIRUS PROTEIN G
WO2019183437A1 (en) 2018-03-23 2019-09-26 North Carolina State University Methods and compositions for antibody to high affinity receptor for ige
EP3829636A1 (en) 2018-07-27 2021-06-09 NGM Biopharmaceuticals, Inc. Use of glucagon receptor antagonists with immunotherapeutic agent
JP2021534239A (ja) * 2018-08-08 2021-12-09 トレリス・バイオサイエンス，エルエルシー Ｒｓｖの改善された受動的および能動的ワクチン
KR102679227B1 (ko) 2019-02-28 2024-06-28 케이엠 바이올로직스 가부시키가이샤 Rsv f/g 키메라 백신
WO2021046390A1 (en) 2019-09-06 2021-03-11 Silgan White Cap LLC Tethered, hinged closure
EP4031171A1 (en) * 2019-09-20 2022-07-27 Universiteit Antwerpen A novel human respiratory syncytial virus strain and its use
EP4429966A1 (en) 2021-11-08 2024-09-18 Silgan White Cap LLC Protrusion on container neck
TW202415409A (zh) * 2022-08-02 2024-04-16 中國商諾納生物（蘇州）有限公司 Msln抗體藥物複合體
WO2025106427A1 (en) * 2023-11-14 2025-05-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing and protective monoclonal antibodies against respiratory syncytial virus (rsv)
WO2025194126A1 (en) * 2024-03-15 2025-09-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Respiratory syncytial virus (rsv) g and f antibodies with high rsv-neutralizing potency

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3734263B2 (ja) * 1993-05-25 2006-01-11 ワイス・ホールディングズ・コーポレイション 呼吸器シンシチウムウイルスに対するワクチンのためのアジュバント
US6020182A (en) * 1996-07-12 2000-02-01 Connaught Laboratories Limited Subunit respiratory syncytial virus vaccine preparation
FR2766192B1 (fr) * 1997-07-17 2001-07-13 Pf Medicament Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie
US6642062B2 (en) 1998-09-03 2003-11-04 Trellis Bioinformatics, Inc. Multihued labels
US7083950B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
CA2359776C (en) 1999-01-22 2010-08-03 Ralph A. Tripp Methods for the prevention and treatment of diseases caused by an inflammatory response mediated by endogenous substance p by using anti-substance p antibodies
ATE412666T1 (de) * 2000-10-18 2008-11-15 Us Gov Health & Human Serv Zusammensetzungen und verfahren zur modulierung von rsv-infektionen und -immunität
US7413868B2 (en) 2003-11-05 2008-08-19 Trellis Bioscience, Inc. Use of particulate labels in bioanalyte detection methods
JP4736037B2 (ja) * 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
CN1986569A (zh) * 2005-12-23 2007-06-27 首都儿科研究所 人源抗呼吸道合胞病毒中和性基因工程Fab抗体
WO2007094423A1 (ja) * 2006-02-15 2007-08-23 Evec Incorporated ヒトサイトメガロウイルスに結合するヒトのモノクローナル抗体並びにその抗原結合部分
KR20080113223A (ko) * 2006-03-06 2008-12-29 심포젠 에이/에스 호흡기세포 융합 바이러스 감염 치료용 재조합 폴리클로날 항체
CA2657123A1 (en) 2006-07-12 2008-01-17 Trellis Bioscience, Inc. Cellspottm applications
NZ585589A (en) * 2007-10-25 2012-07-27 Trellis Bioscience Inc Anti-rsv g protein antibodies

Also Published As

Publication number Publication date
AU2008316703A2 (en) 2010-07-22
AU2008316703B2 (en) 2012-09-27
RU2010120879A (ru) 2011-11-27
JP5808536B2 (ja) 2015-11-10
CA2703667A1 (en) 2009-04-30
US8273354B2 (en) 2012-09-25
WO2009055711A2 (en) 2009-04-30
IL205257A (en) 2014-12-31
JP2015078231A (ja) 2015-04-23
US20090130120A1 (en) 2009-05-21
US20130034564A1 (en) 2013-02-07
ZA201003131B (en) 2011-03-30
WO2009055711A3 (en) 2009-09-24
US20100285022A1 (en) 2010-11-11
RU2526517C2 (ru) 2014-08-20
BRPI0819210A2 (pt) 2015-06-23
CN101808663A (zh) 2010-08-18
CN101808663B (zh) 2015-09-30
IL205257A0 (en) 2010-12-30
US7736648B2 (en) 2010-06-15
EP2214711A2 (en) 2010-08-11
KR20100091195A (ko) 2010-08-18
EP2214711A4 (en) 2011-12-21
US9321830B2 (en) 2016-04-26
EP2214711B1 (en) 2018-08-15
JP2011500091A (ja) 2011-01-06
NZ585589A (en) 2012-07-27
KR101671452B1 (ko) 2016-11-17
AU2008316703A1 (en) 2009-04-30
CA2703667C (en) 2015-12-29

Similar Documents

Publication Publication Date Title
MX2010004482A (es) Anticuerpos anti-proteina g vsr.
WO2011143624A3 (en) Humanized and chimeric monoclonal antibodies to cd47
MX2012001882A (es) Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso.
PH12016500859B1 (en) Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
MX2011012060A (es) Anticuerpos humanizados específicos de la forma protofibrilar del péptido beta-miloide.
WO2010113117A3 (en) Preparation of isolated agonist anti-edar monoclonal antibodies
MX2010003574A (es) Anticuerpos il-23.
UA109658C2 (xx) Антитіло проти cgrp
MX2009011500A (es) Anticuerpos anti-mdl-1.
UA109633C2 (uk) Антитіло людини проти тканинного фактора
ECSP13012436A (es) ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
WO2010054265A3 (en) Monoclonal antibodies to fibroblast growth factor receptor 2
WO2010136311A3 (en) Compositions and methods for antibodies targeting complement protein c3b
WO2011147982A3 (en) Monoclonal antibodies against her2 epitope
WO2009002947A3 (en) Compounds and peptides that bind the trail receptor
MY156286A (en) Human il-23 antigen binding proteins
PT2126049E (pt) Anticorpos contra citomegalovírus humano (hcmv)
UA113623C2 (uk) Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi)
TN2009000380A1 (en) Novel human anti-r7v antibodies and uses thereof
WO2008043052A3 (en) Human antibodies neutralizing human metapneumovirus
WO2009114560A3 (en) Compositions and methods for the therapy and diagnosis of cytomegalovirus infections
NZ594347A (en) Antibodies against human tweak and uses thereof
WO2009115509A3 (en) Antigenic protein fragments of streptococcus pneumoniae
MX2013002718A (es) Composiciones de anticuerpo anti-vegfr-3.
WO2010117455A3 (en) Human monoclonal antibodies protective against bubonic plaque

Legal Events

Date Code Title Description
FG Grant or registration